Journal of Diabetes Research

Journal of Diabetes Research / 2013 / Article
Special Issue

Animal Models of Diabetes and its Associated Complications

View this Special Issue

Research Article | Open Access

Volume 2013 |Article ID 498925 | 13 pages |

Glomerulopathy in the KK.Cg-Ay/J Mouse Reflects the Pathology of Diabetic Nephropathy

Academic Editor: Daisuke Koya
Received23 Jan 2013
Accepted15 Mar 2013
Published24 Apr 2013


The KK.Cg- /J (KK- ) mouse strain is a previously described model of type 2 diabetes with renal impairment. In the present study, female KK- mice received an elevated fat content diet (24% of calories), and a cohort was uninephrectomized (Unx) to drive renal disease severity. Compared to KK- controls, 26-week-old KK- mice had elevated HbA1c, insulin, leptin, triglycerides, and cholesterol, and Unx further elevated these markers of metabolic dysregulation. Unx KK- mice also exhibited elevated serum BUN and reduced glomerular filtration, indicating that reduction in renal mass leads to more severe impairment in renal function. Glomerular hypertrophy and hypercellularity, mesangial matrix expansion, podocyte effacement, and basement membrane thickening were present in both binephric and uninephrectomized cohorts. Glomerular size was increased in both groups, but podocyte density was reduced only in the Unx animals. Consistent with functional and histological evidence of increased injury, fibrotic (fibronectin 1, MMP9, and TGFβ1) and inflammatory (IL-6, CD68) genes were markedly upregulated in Unx KK- mice, while podocyte markers (nephrin and podocin) were significantly decreased. These data suggest podocyte injury developing into glomerulopathy in KK- mice. The addition of uninephrectomy enhances renal injury in this model, resulting in a disease which more closely resembles human diabetic nephropathy.

1. Introduction

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) and is associated with high cardiovascular risk and significant morbidity and mortality [1, 2]. Disease progression is difficult to predict, as rates of decline in glomerular filtration rate (GFR) are variable in this patient population and only one-third of diabetic patients, the majority of whom have type 2 diabetes (T2D), develop progressive renal failure. The pathogenesis of DN is mediated by a complex interplay of genetic and environmental modifiers resulting in hemodynamic and structural changes in the kidney that contribute to progressive functional loss in both the glomerulus and tubular-interstitial epithelium [3, 4]. Central to disease progression is glomerular injury, with pathological changes including glomerular hypertrophy, glomerular basement membrane (GBM) thickening, mesangial matrix expansion, and subsequent glomerulosclerosis [3]. Podocytes are critical to the functional glomerular filtration barrier and are particularly sensitive to damage by the “diabetic milieu” of dysglycemia, dyslipidemia, hemodynamic changes, and inflammation [5, 6]. In both T1 and T2D patients, podocyte detachment and loss are associated with decline in glomerular function [79].

While rodent DN models have provided significant insight into renal disease pathophysiology, no model captures all the features of human DN [1013], creating an obstacle to understanding disease etiology and to developing effective treatments [14]. To address this, the NIH-sponsored Animal Models of Diabetic Complications Consortium (AMDCC) committee was formed to establish phenotyping standards and validation criteria for available murine models of DN ( The committee defined criteria for mouse models of DN that reflect human disease, including greater than 50% decline in GFR over the lifetime of the animal model, 10-fold increase in albuminuria relative to age- and gender- matched controls, and renal pathology characterized by advanced mesangial matrix expansion, arteriolar hyalinosis, and glomerular basement membrane thickening [10, 11]. While numerous diabetic murine models were phenotyped and met some of the criteria, no one model fulfilled all of the AMDCC criteria. The committee consequently recommended the use of a “suite” of mouse models, each recapitulating individual features of renal disease in diabetic patients [11, 15].

One of the mouse models not extensively examined by the AMDCC is the strain. This model exhibits marked obesity, glucose intolerance, severe insulin resistance, dyslipidemia, and hypertension [1618]. mice also develop renal disease characterized by moderate albuminuria with mild glomerular pathology and podocyte loss [1921]. Several therapeutic interventions have been reported to reduce albuminuria and improve renal pathology in this model, including renin-angiotensin blockage [18, 22, 23], statin therapy [24], and vitamin D [25]. However, direct measurement of GFR in this model has not been reported and is an important component, as decline in GFR is the benchmark of disease progression, and prevention of decline in GFR is a key efficacy endpoint in therapeutic clinical trials [26, 27].

The goal of this study was to increase renal disease severity in the model by multiple “hits,” each reflecting a known factor contributing to diabetes and its complications in humans. We combined dietary manipulation and reduction in renal mass to increase renal injury in this model. Together, these environmental modifiers exacerbate glomerular and tubulointerstitial pathology, increase podocyte loss, and reduce GFR in mice, and our findings support the use of this multifactorial approach in developing appropriate models for human diabetic nephropathy.

2. Materials and Methods

2.1. Experimental Animals

All animal studies followed the principles of laboratory animal care established by the National Institutes of Health and the Institutional Animal Care and Use Committee (IACUC). Female (further referred as ) and littermate control KK-a/a mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and acclimated for 3 weeks before the beginning of the study. Cohorts of mice were uninephrectomized at 8 weeks of age. At 9 weeks, animals were placed on semipurified control diet (D08112307) containing 12% k/cal fat or a moderately high-fat diet containing 24% k/cal fat and 0.2% cholesterol (D10011701) (Research Diets Inc., St. Louis, MO, USA). Mice were randomized according to albumin/creatinine at 12 weeks of age and were sacrificed at 26 weeks of age.

2.2. Physiological and Biochemical Characterization

Blood pressure was measured at 11 and 22 weeks of age by a noninvasive tail cuff CODA system (Kent Scientific, Torrington, CT, USA) after the mice were externally prewarmed for 10 min at 37°C. Animals were trained once daily, 4 days prior to recorded measurements. Eight to twenty recordings were taken for each measurement.

Fasting blood samples were collected by retroorbital sinus bleeds. Collected samples were separated to serum or EDTA plasma or kept as whole blood. Glycated hemoglobin (HbA1c), serum and urine creatinine, blood urea nitrogen (BUN), serum cholesterol, and triglycerides were measured using a Cobas 400 plus bioanalyzer (Roche Diagnostics, IN, USA). Blood was also collected from the tail vein from unanesthetized, nonfasted animals for the measurement of blood glucose using a glucometer. Body weight (BW) was measured weekly. Urine samples were collected for 24 h using metabolic cages. Urine albumin was measured by immunoassay Albuwell M (Exocell Inc., Philadelphia, PA, USA). Immuno-ELISA according to manufacturer’s instructions was used to measure serum adiponectin and insulin (ALPCO Diagnostics, Salem, NH, USA), PAI-1 (Molecular Innovations, Novi, MI, USA), urine nephrin (Exocell Inc., Philadelphia, PA, USA), and KIM-1 (Immunology Consultants Laboratory, Inc. Portland, OR, USA).

2.3. Glomerular Filtration Rate

Glomerular filtration rate (GFR) was performed at 23 weeks of age using a FIT-GFR Test Kit for Inulin according to the manufacturer’s instructions (BioPal, Worcester, MA, USA). A 5 mg/kg bolus intraperitoneal injection of inulin was given, followed by serial saphenous bleeds at 30, 60, and 90 minutes. Serum was isolated and quantified on inulin ELISA. Inulin serum clearance was determined by nonlinear regression using a one-phase exponential decay formula ( ), and GFR was calculated (GFR = ((I)/(B/b))/KW, where I is the amount of inulin delivered by the bolus injection, B is y-intercept, b is the decay constant, x is time, and KW is kilo weight of the animal).

2.4. Histological Assessment

Formalin-fixed, paraffin-embedded kidneys were sectioned at 3 microns and stained with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), and Masson’s Trichrome for histological analysis. Slides were evaluated by a veterinary pathologist. Glomerular and tubular pathology, interstitial inflammation including presence of CD68 immunolabeled macrophages, and interstitial fibrosis were semiquantitatively scored on a scale of 0–4 as follows: 0 = normal; 1 = mild; 2 = moderate; 3 = marked; 4 = severe. Statistical analysis was performed using the nonparametric Kruskal-Wallis test followed by Dunn’s multiple comparison test.

2.5. Immunohistochemistry

Immunohistochemistry was performed on paraffin-embedded kidney sections. Anti-CD68 immunohistochemistry staining was performed on a Leica Bond MAX automated immunostainer (Leica Microsystems Inc. Buffalo Grove, IL, USA). Tissue sections were dewaxed, treated with Proteinase K enzyme, and followed by blocking with peroxidase and then serum. Slides were incubated in CD68 Clone Fa-11 (Abcam, Cambridge, MA, USA) antibody for 30 minutes, followed by rabbit anti-rat antibody, then a goat anti-rabbit HRP polymer for 15 minutes. Chromogen visualization was performed using 3,3′-diaminobenzidine tetrahydrochloride (DAB) for 3–5 minutes, followed by hematoxylin counterstain (all components were from Leica, unless otherwise noted). 0.05% Tween 20/Tris-buffered saline (DAKO, Carpinteria, CA, USA) washes were performed between all steps. Podocyte counting was assessed using anti-WT1 (Wilms Tumor 1) clone 6F-H2 at 1 : 100 dilution (Dako). Immunohistochemistry was performed on a Leica Bond MAX automated immunostainer (Leica Microsystems Inc. Bannockburn, IL, USA). 0.05% Tween 20/Tris-buffered saline (DAKO) washes were performed between all steps. Tissue sections were dewaxed and treated with Proteinase K enzyme then peroxidase. Tissues were then treated with rodent block (BioGenex, Fremont, CA, USA), anti-WT-1 primary antibody was detected using mouse on mouse HRP polymer. Chromogen visualization was performed using 3,3′-diaminobenzidine tetrahydrochloride (DAB) for 5 minutes, followed by hematoxylin counterstain and dehydration through increasing ethanol-water gradient to xylene and mounted in Permount (Fisher Scientific, Pittsburg, PA, USA). Whole kidney sections were imaged using Aperio ScanScope (Aperio Technologies, Vista, CA, USA). Greater than 50 glomeruli per kidney section were quantitated for the number of WT-1-positive (brown) and WT-1-negative cells (blue). Software analysis was done using custom algorithm on Spectrum Version (Aperio Technologies).

2.6. Transmission Electron Microscopy

For ultrastructural analysis, 1 mm3 samples of kidney cortex were fixed in 3% glutaraldehyde in 0.2 M cacodylate buffer (Electron Microscopy Sciences, Hatfield, PA, USA) and embedded in epon. Semithin 1 micron sections were stained with Richardson’s stain (made up of methylene blue CI-52015, azure II, and borax, (Sigma, St. Louis, MO, USA)) and evaluated via high resolution light microscopy. Ultrathin sections were cut at 70 nm and mounted on 200 mesh copper grids. The grids were stained on a Leica EM AC20 Stainer (Leica Microsystems) with 0.5% aqueous uranyl acetate and 3% lead citrate solution (Leica). Images were acquired on a JEOL JEM-1400 transmission electron microscope (JEOL; Peabody, MA, USA) using a Gatan 785 Erlangshan ESW1000 digital camera (Gatan, Inc.; Pleasanton, CA, USA).

2.7. Transcriptional Analysis

Quantitative transcriptional analysis of kidney tissue from animals at 26 weeks of age was performed on TaqMan Custom Array microarrays using 7900HT Fast real-time PCR system. Kidney mRNA purification was performed by homogenizing 50–100 mg of tissue in 1 mL of TRIzol reagent. Samples were left for 5 minutes at 15 to 30°C followed by the addition of 0.2 mL chloroform (Sigma). Samples were mixed vigorously, left at room temperature for 3 minutes followed by centrifugation at 12,000  g for 15 minutes at 4°C. The aqueous phase was taken, and RNA was precipitated with 0.5 mL of isopropyl alcohol (Sigma). The pellet was washed once with 1 mL 75% ethanol, air-dried, and redissolved in RNase-free water. Samples were DNAse treated using TurboDNase according to manufacturer’s instructions. RNA was qualified on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). All items were obtained from Life Technologies, Grand Island, NY, USA unless otherwise noted.

3. Results

3.1. Uninephrectomized KK-Ay Mice Are Obese and Exhibit Evidence of Metabolic Abnormalities

Diabetes and renal injury are more severe in male versus female mice [28] and, as a consequence, preclinical studies typically focus on males. However, male develop obstructive uropathy and hydronephrosis [29] and exhibit impaired glucose tolerance [28]. To avoid these urological issues, all studies described here use female mice. This also allowed us to use KK-a/a females as nondiabetic, strain-matched controls, as female KK-a/a mice maintain normal glycemic control, while male KK-a/a are insulin resistant [30].

While on standard chow, mice were significantly heavier than control or uninephrectomized (Unx) KK-a/a animals (Figure 1(a)). After switching to the elevated fat diet, KK-a/a + Unx mice gained weight relative to KK-a/a controls, but were less obese than both groups. Blood pressure, measured in 11-and 22-week-old mice, was unchanged in both the KK-a/a and + Unx groups, and no difference was observed between the two cohorts. At 11 weeks, KK-a/a mean arterial pressure (MAP) was  mmHg, while + Unx MAP was  mmHg. At 22 weeks, MAP in KK-a/a mice was  mmHg and + Unx MAP was  mmHg.

In KK-a/a controls, glycated hemoglobin (HbA1c) was unaffected by the switch to an elevated fat diet (Figure 1(b)). Serum HbA1c levels were elevated in all mice on standard chow, and serum HbA1c further increased after the switch to the elevated fat diet, with peak levels occurring between 5 and 10 weeks after diet change. While serum HbA1c levels were higher in uninephrectomized ( + Unx) mice than in KK-a/a, these levels were consistently lower compared to birenal , a likely consequence of elevated insulin levels in the + Unx animals (Figure 1(c)). Consistent with the HbA1c levels, blood glucose in nonfasted, unanesthetized animals was also significantly elevated in the + Unx group relative to KK-a/a mice (318.8+/26.3 versus 222.3+/−20.3, ). However, to avoid undue stress caused by unanesthetized blood collection, and because we note short-term variability in glucose values as mice are moved into the metabolic cages for urine collection, glycemia was followed in this study using HbA1c. Serum adiponectin levels were reduced at 16 weeks of age in both groups, which were further decreased at 26 weeks (Figure 1(d)). Interestingly, uninephrectomy in the KK-a/a mice was also associated with a sharp decline in adiponectin levels between 20 and 26 weeks of age.

Consistent with increased body weight, serum lipids and adiposity-associated cytokines were elevated in mice. Serum leptin was elevated 2-fold relative to KK-a/a controls in binephric mice and approximately 5-fold in + Unx animals (Figure 2(a)). Serum leptin was also elevated by Unx in both KK-a/a and . Serum triglyceride levels show a similar profile: both KK-a/a and uninephrectomized mice were hypertriglyceridemic compared to binephric animals, and triglycerides were higher in mice than in comparable KK-a/a. + Unx triglycerides were elevated 4.5-fold versus binephric KK-a/a controls (Figure 2(b)). Serum cholesterol levels were also markedly elevated in + Unx mice (Figure 2(c)) and further increased by uninephrectomy, an effect consistent with that observed for serum leptin and triglycerides. In contrast, serum PAI-1 levels were not affected by uninephrectomy (Figure 2(d)), but were significantly elevated in mice relative to KK-a/a. Taken together, these data are consistent with the metabolic profile of human T2DN [2, 31, 32].

3.2. Urine and Serum Biomarkers Indicate Renal Injury in KK-Ay and KK-Ay + Unx Mice

mice exhibit consistent and progressive albuminuria, measured as albumin/creatinine ratio (ACR) (Figure 3(a)). ACRs were comparable in both and + Unx, suggesting that uninephrectomy does not affect albuminuria in animals. Urinary excretion of the podocyte protein nephrin, recently identified as a biomarker of glomerular injury in both humans and mice [33, 34], was elevated in both and + Unx mice at 26 weeks (14 weeks after the switch to elevated fat diet), with a trend towards nephrinuria first detected at 22 weeks (Figure 3(b)). As with ACR, we observed no difference in urinary nephrin/creatinine ratio in intact and uninephrectomized mice, suggesting glomerular injury in both groups.

We also examined the concentration of KIM-1, a marker of ongoing renal tubular injury [35, 36], in urine collected from 26-week-old mice (Figure 3(c)). Relative to KK-a/a animals, KIM-1 was elevated in both and + Unx mice. Interestingly, KIM-1 levels in + Unx animals were lower than in their binephric counterparts, possibly as a consequence of the reduced renal mass in uninephrectomized mice.

Elevated ACR and urine nephrin and KIM-1 concentrations suggest renal glomerular and tubular injury in mice. To determine whether renal function was affected, we examined serum blood urea nitrogen (BUN) levels in these animals (Figure 4(a)). BUN was of normal range in KK-a/a mice, but was slightly elevated in KK-a/a + Unx and animals. Mice in the + Unx group, however, showed substantially greater increases in BUN, reaching an average of 45.3 mg/dL at 26 weeks ( versus both and KK-a/a). These BUN values suggest impaired renal function in + Unx mice, and we therefore directly measured glomerular filtration rate (GFR) in this group. We found a 32% reduction in GFR in + Unx mice compared to KK-a/a littermate controls, a reduction roughly equivalent to late stage 2 CKD in human patients. Thus, despite the finding that urine biomarkers revealed little difference in the extent of renal damage between and + Unx mice, changes in BUN and GFR, both direct indicators of renal function, indicated substantial renal impairment only in + Unx mice.

3.3. Uninephrectomy Exacerbates Glomerulopathy and Renal Fibrosis Markers in KK-Ay Mice

On histologic assessment, nondiabetic KK-a/a control mice exhibited minimal to mild glomerulopathy that was unchanged by elevated fat diet and Unx (Figures 5(a) and 5(b)). In contrast, diabetic mice fed elevated fat diet exhibited a moderate to marked glomerulopathy (Figure 5(c)), characterized predominantly by segmental to global expansion of the mesangial matrix by PAS positive material and hypercellularity of the glomerular tuft. Semiquantitative scoring (Figure 5(i)) demonstrated a significant increase in the glomerulopathy in binephric diabetic mice versus KK-a/a controls ( ), and this was further exacerbated by uninephrectomy in the + Unx group ( vs. KK-a/a controls). Tubular lesions were rare to nonexistent in nondiabetic KK-a/a groups (Figures 5(e) and 5(f)). However, uninephric and binephric groups exhibited multifocal tubular atrophy with thickened tubular basement membranes (Figures 5(g) and 5(h)), tubular dilation with or without luminal protein casts, and tubular mineralization at the corticomedullary junction. Overall, the tubular pathology was significantly greater in binephric ( ) and uninephric mice ( , Figure 5(j)) relative to the KK-a/a controls. In the interstitium, diabetic mice in both groups had multifocal infiltration of mixed inflammatory cells and mild fibrosis which typically surrounded severely affected glomeruli and/or tubules (Figures 5(g) and 5(h)). Inflammatory infiltrates were composed of macrophages, lymphocytes, and plasma cells admixed with occasional neutrophils. Although group median scores for interstitial fibrosis were similar in binephric and uninephric groups, only the uninephric group showed a statistically significant increase relative to the KK-a/a controls ( , not shown).

To further examine whether uninephrectomy affects fibrosis in mice, we measured transcription of fibrosis-related genes in total kidney mRNA (Figure 5(k)). In animals, we observed the upregulation of RNA encoding Col3a1, Fn1, PAI-1, Mmp9, and RNA encoding the TGFβ1-3 ligands relative to KK-a/a controls. In + Unx mice, we saw an additional statistically significant increase in Col3a1 and Mmp9 expression relative to binephric animals, as well as a trend towards increased expression of the remaining fibrotic genes assessed. Taken together, these data indicate renal fibrosis in mice and that uninephrectomy further exacerbates renal damage in this model.

3.4. Podocyte Injury in KK-Ay + Unx Mice

At the ultrastructural level, KK-a/a mice showed normal podocyte foot processes (Figure 6(a)) and a smooth, trilaminar glomerular basement membrane (GBM). Both and + Unx animals exhibited multifocal podocyte foot process effacement and areas of irregular thickening in the lamina densa of the GBM (Figures 6(b) and 6(c)). Because podocyte foot process effacement is reversible [37, 38], we used morphometric analysis of sections immunostained for the podocyte marker WT-1 to assess podocyte loss in mice. No change was observed in average cell density per glomerulus in any of the groups examined (Figure 6(d)). However, we noted increased glomerular area in and + Unx mice. Furthermore, we observed a 28% decrease in the density of WT-1 positive cells per mm2 glomerular area in uninephrectomized animals compared to KK-a/a mice (Figure 6(f)). This decrease in podocyte density was not observed in binephric animals, a distinction consistent with the higher glomerular pathology scores in + Unx mice (Figure 5(i)) and suggesting that addition of uninephrectomy exacerbates glomerular injury in the model of diabetic nephropathy.

Examination of podocyte-specific transcripts further supports the conclusion that podocyte loss is observed only in + Unx mice. Using quantitative RT-PCR, we measured expression of the podocyte-specific genes nephrin (Nphs1), podocin (Nphs2), and WT-1 in total kidney mRNA (Figure 6(g)). We observed no difference in the expression of any of these genes between KK-a/a and binephric mice, but note a statistically significant decrease in all three podocyte markers in + Unx animals. These data are consistent with the decrease in podocyte density in + Unx mice and suggest that uninephrectomy is necessary to induce podocyte loss in this model.

3.5. Increased Macrophage Infiltration and Inflammation in Uninephrectomized KK-Ay Mice

Macrophage infiltration and inflammation are increasingly recognized as important elements in diabetic glomerular disease [39]. To examine whether renal macrophage infiltration is present in the model, immunohistochemistry for the macrophage marker CD68 was performed on kidney sections (Figure 7). In KK-a/a or KK-a/a + Unx mice, there were scattered CD68+ macrophages in the interstitium (Figures 7(a) and 7(b)) and rare CD68 positive cells in glomeruli. In contrast, binephric mice (Figure 7(c)) exhibited a significant increase in interstitial CD68+ macrophages ( versus KK-a/a controls) and this was enhanced in the + Unx group ( versus KK-a/a controls, Figure 7(f)). Both diabetic groups had low numbers of CD68+ cells within glomeruli (Figure 7(e)). These may represent infiltrating macrophages or, alternatively, mesangial cells transforming to a macrophage phenotype.

Immunohistochemical findings were corroborated by quantitative RT-PCR from total kidney mRNA which indicated a significant increase in the expression of CD68 and inflammation-associated markers IL-6, MCP-1, and CD44 in both and + Unx animals (Figure 7(g)). Expression of each of these markers was further increased in + Unx mice, pointing to increased renal inflammation in this group.

4. Discussion

The mouse strain is glucose intolerant, severely insulin resistant, dyslipidemic, and hypertensive; all are characteristics of the “metabolic syndrome” phenotype of T2D patients [2426]. Evidence of kidney injury is also present, including albuminuria, mesangial matrix accumulation, and GBM thickening [20]. However, as with many mouse models of diabetic nephropathy [10, 11], renal damage in mice is mild and does not adequately capture key aspects of the human disease. To drive disease severity in , we provided a diet containing 24% of calories from fat and examined the effects of uninephrectomy (Unx) on metabolic and renal endpoints in this model. We found that while urinary markers of renal injury (albuminuria, nephrinuria, and urine Kim-1) were similar in and + Unx mice, uninephrectomized animals exhibited increased glomerular pathology, podocyte damage and loss, and renal inflammation. Furthermore, + Unx mice had elevated serum BUN and reduced GFR, indicating the impairment of renal function. Our findings indicate that + Unx mice have a more severe phenotype than previously reported in other DN models and, therefore, is a representative model of progressive glomerular injury and podocyte loss.

Our strategy was to use reduction in renal mass and dietary manipulation in a strain which is genetically susceptible to renal disease to further exacerbate renal injury. First, mice were uninephrectomized to induce glomerular hypertrophy, distortion of capillary architecture, and increased mechanical stress on the podocyte, factors which have been shown to exacerbate glomerulosclerosis [40, 41]. mice were then fed a semipurified diet that is more representative of a normal human diet, with 24% of calories derived from fat. Excess dietary fat promotes tissue injury [42], and the very low fat content in normal rodent chow may consequently be protective. This elevated fat diet is also low in phytoestrogens, which are present in high levels in normal rodent chow [43] and can induce hormonal and antioxidant effects [44] that may blunt progressive injury.

A significant advantage to using the strain is that diabetes is polygenic and not due to a defect in leptin receptor signaling. This is analogous to human disease and in contrast to other obese diabetic models such as db/db and ob/ob mice [10, 17]. We found that both binephric and uninephrectomized animals have elevated HbA1c, insulin, and leptin levels, suggesting both insulin and leptin resistance. We also observed a reduction in serum levels of the anti-inflammatory cytokine adiponectin [31, 45] and elevation of the proinflammatory cytokine PAI-1 [32, 46] in both cohorts of mice, suggesting the presence of a proinflammatory state similar to human diabetic patients [47]. Inflammation may be exacerbated in + Unx mice, as serum insulin and leptin levels (and, consequently, triglycerides) were further elevated in these animals. Taken together, these data indicate metabolic dysfunction and inflammation in both and + Unx cohorts, and suggest that uninephrectomy heightens inflammation in this model.

Urinalysis of and + Unx mice indicated renal injury in both groups. Albumin/creatinine ratios (ACRs) were elevated relative to KK-a/a controls, and increased levels of urine nephrin, a marker of podocyte injury in preclinical models and in human patients [48, 49], were also detected. Together, these findings suggest the impairment of the glomerular filtration barrier in mice. Kim-1, a marker of proximal tubule injury [36], was also elevated in and + Unx. We note, however, that Kim-1 in urine from + Unx mice was slightly, but statistically significantly, decreased relative to , possibly reflecting the reduced renal mass in the uninephrectomized mice.

While urine markers of renal injury were similar in both cohorts, renal function appeared to be more significantly impaired in the Unx group. Serum BUN is a routine laboratory test for diagnosis and routine followup of patients with CKD [50] and was elevated in + Unx mice. Furthermore, glomerular filtration rate (GFR) was decreased by 33% versus nondiabetic KK-a/a. Such loss of renal function, roughly comparable to late stage CKD stage 2 [51], suggests that + Unx mice exhibit the progressive renal injury characteristic of human diabetic nephropathy.

Consistent with previous reports [20, 21], nonnephrectomized mice displayed significant glomerulopathy and mild to moderate tubulointerstitial pathology. + Unx animals had higher median glomerular pathology scores, indicating that addition of Unx exacerbates the severity of glomerulopathy in this model. While tubulointerstitial pathology is not quantifiably different in the two groups, expression of the fibrotic markers Col3a1 and Mmp9 is statistically significantly elevated, and we note a trend towards increased expression of a number of additional fibrotic genes.

Both and + Unx animals exhibited multifocal podocyte foot process effacement and areas of irregular GBM thickening, but we observed a 28% decrease in the density of WT-1+ cells only in the + Unx group, indicating podocyte loss in these mice. Reduced RNA expression of WT-1 and of the podocyte-specific markers nephrin (nphs1) and podocin (nphs2) in + Unx further support this conclusion. We note, however, that despite the evidence of podocyte loss in + Unx mice, the concentration of urine nephrin was similar in both cohorts, suggesting that, while elevated urine nephrin indicated ongoing glomerular injury, the absolute level of nephrinuria may not distinguish relative degrees of podocyte injury. Alternatively, because reduction of renal mass in + Unx animals halves the total number of podocytes, potentially contributing to urinary nephrin, equivalent levels of nephrinuria may actually reflect a much higher rate of podocyte loss in + Unx mice. Nevertheless, taken together, these data attest measurable podocyte loss only in the + Unx group, suggesting that uninephrectomy is necessary to induce podocyte loss in the model.

Our data also indicate that uninephrectomy heightened renal inflammation in this model. Immunostaining for the macrophage marker CD68 revealed a statistically significant increase in CD68+ macrophages in the interstitium of diabetic mice, with a trend for greater infiltration in the uninephric versus the binephric group. Furthermore, RNA expression of CD68, as well as of the inflammation-associated markers IL-6 and MCP-1, was significantly greater in the + Unx group. These data all point to increased renal inflammation in Unx- mice as a contributory factor in the enhanced renal phenotype in this model.

The results of this study support a strategy for DN model development, complementary to the AMDCC’s recommendation, in which multiple “hits” were layered together to exacerbate renal pathology in mouse models genetically predisposed to diabetes. Such an approach may more realistically capture the interaction between genetics and environment contributing to the complex pathogenesis of diabetic nephropathy.

Conflict of Interests

All authors are employed by Genzyme, a Sanofi company. There are no other competing interests to disclose.


  1. A. J. Collins, R. N. Foley, B. Chavers et al., “US renal data system 2011 Annual data report,” American Journal of Kidney Diseases, vol. 59, no. 1, pp. e1–e26, 2012. View at: Publisher Site | Google Scholar
  2. A. Whaley-Connell, J. R. Sowers, P. A. McCullough et al., “Diabetes mellitus and CKD awareness: the kidney early evaluation program (KEEP) and national health and nutrition examination survey (NHANES),” American Journal of Kidney Diseases, vol. 53, no. 4, pp. S11–S21, 2009. View at: Publisher Site | Google Scholar
  3. P. Fioretto and M. Mauer, “Histopathology of diabetic nephropathy,” Seminars in Nephrology, vol. 27, no. 2, pp. 195–207, 2007. View at: Publisher Site | Google Scholar
  4. T. W. C. Tervaert, A. L. Mooyaart, K. Amann et al., “Pathologic classification of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 556–563, 2010. View at: Publisher Site | Google Scholar
  5. G. R. Reddy, K. Kotlyarevska, R. F. Ransom, and R. K. Menon, “The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy?” Current Opinion in Nephrology and Hypertension, vol. 17, no. 1, pp. 32–36, 2008. View at: Publisher Site | Google Scholar
  6. H. Makino, Y. Miyamoto, K. Sawai et al., “Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone,” Diabetes, vol. 55, no. 10, pp. 2747–2756, 2006. View at: Publisher Site | Google Scholar
  7. M. Toyoda, B. Najafian, Y. Kim, M. L. Caramori, and M. Mauer, “Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy,” Diabetes, vol. 56, no. 8, pp. 2155–2160, 2007. View at: Publisher Site | Google Scholar
  8. M. E. Pagtalunan, P. L. Miller, S. Jumping-Eagle et al., “Podocyte loss and progressive glomerular injury in type II diabetes,” Journal of Clinical Investigation, vol. 99, no. 2, pp. 342–348, 1997. View at: Google Scholar
  9. K. E. White, R. W. Bilous, and On Behalf of the Diabiopsies Study Group, “Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients,” Nephrology Dialysis Transplantation, vol. 19, no. 6, pp. 1437–1440, 2004. View at: Publisher Site | Google Scholar
  10. M. D. Breyer, E. Böttinger, F. C. Brosius et al., “Mouse models of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 27–45, 2005. View at: Publisher Site | Google Scholar
  11. F. C. Brosius, C. E. Alpers, E. P. Bottinger et al., “Mouse models of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2503–2512, 2009. View at: Publisher Site | Google Scholar
  12. C. Rüster and G. Wolf, “Models of diabetic nephropathy,” Drug Discovery Today, vol. 7, no. 1-2, pp. 35–41, 2010. View at: Publisher Site | Google Scholar
  13. M. J. Soler, M. Riera, and D. Batlle, “New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy,” Experimental Diabetes Research, vol. 2012, Article ID 218917, 9 pages, 2012. View at: Publisher Site | Google Scholar
  14. M. D. Breyer, “Progress in progression?” Journal of the American Society of Nephrology, vol. 21, no. 9, pp. 1414–1416, 2010. View at: Publisher Site | Google Scholar
  15. D. Schlöndorff, “Choosing the right mouse model for diabetic nephropathy,” Kidney International, vol. 77, no. 9, pp. 749–750, 2010. View at: Publisher Site | Google Scholar
  16. A. R. Diani, G. A. Sawada, B. A. Hannah et al., “Analysis of pancreatic islet cells and hormone content in the spontaneously diabetic KK Ay mouse by morphometry, immunocytochemistry and radioimmunoassay,” Virchows Archiv, vol. 412, no. 1, pp. 53–61, 1987. View at: Google Scholar
  17. G. Chakraborty, S. Thumpayil, D. E. Lafontant, W. Woubneh, and J. H. Toney, “Age dependence of glucose tolerance in adult KK-A y mice, a model of non-insulin dependent diabetes mellitus,” Lab Animal, vol. 38, no. 11, pp. 364–368, 2009. View at: Publisher Site | Google Scholar
  18. T. Yamazaki, M. Tanimoto, T. Gohda et al., “Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KK-Ay/Ta mice,” Nephron, vol. 113, no. 2, pp. e66–e76, 2009. View at: Publisher Site | Google Scholar
  19. A. R. Diani, G. A. Sawada, N. Y. Zhang et al., “The KKA(y) mouse: a model for the rapid development of glomerular capillary basement membrane thickening,” Blood Vessels, vol. 24, no. 6, pp. 297–303, 1987. View at: Google Scholar
  20. M. Okazaki, Y. Saito, Y. Udaka et al., “Diabetic nephropathy in KK and KK-Ay mice,” Experimental Animals, vol. 51, no. 2, pp. 191–196, 2002. View at: Publisher Site | Google Scholar
  21. T. Ito, M. Tanimoto, K. Yamada et al., “Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy,” Nephrology, vol. 11, no. 1, pp. 29–35, 2006. View at: Publisher Site | Google Scholar
  22. T. Shiuchi, T. X. Cui, L. Wu et al., “ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO,” Hypertension, vol. 40, no. 3, pp. 329–334, 2002. View at: Publisher Site | Google Scholar
  23. M. Sasaki, S. Uehara, H. Ohta et al., “Losartan ameliorates progression of glomerular structural changes in diabetic KK Ay mice,” Life Sciences, vol. 75, no. 7, pp. 869–880, 2004. View at: Publisher Site | Google Scholar
  24. M. Matsumoto, M. Tanimoto, T. Gohda et al., “Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice,” Metabolism, vol. 57, no. 5, pp. 691–697, 2008. View at: Publisher Site | Google Scholar
  25. I. Ohara, M. Tanimoto, T. Gohda et al., “Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D3 in type 2 diabetic nephropathy in KK-A y/Ta mice,” Nephron, vol. 117, no. 4, pp. e124–e132, 2011. View at: Publisher Site | Google Scholar
  26. L. F. Fried, W. Duckworth, J. H. Zhang et al., “Design of combination angiotensin receptor blocker and angiotensin- converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D),” Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 361–368, 2009. View at: Publisher Site | Google Scholar
  27. H.-H. Parving, B. M. Brenner, J. J. V. McMurray et al., “Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1663–1671, 2009. View at: Publisher Site | Google Scholar
  28. J. I. Suto, S. Matsuura, K. Imamura, H. Yamanaka, and K. Sekikawa, “Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-A(y) mice,” European Journal of Endocrinology, vol. 139, no. 6, pp. 654–661, 1998. View at: Publisher Site | Google Scholar
  29. H. Ninomiya, T. Inomata, and K. Ogihara, “Obstructive uropathy and hydronephrosis in male KK-Ay mice: a report of cases,” Journal of Veterinary Medical Science, vol. 61, no. 1, pp. 53–57, 1999. View at: Google Scholar
  30. M. Nakamura and K. Yamada, “Studies on a diabetic (KK) strain of the mouse,” Diabetologia, vol. 3, no. 2, pp. 212–221, 1967. View at: Publisher Site | Google Scholar
  31. B. Becker, F. Kronenberg, J. T. Kielstein et al., “Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1091–1098, 2005. View at: Publisher Site | Google Scholar
  32. H. Ha, E. Y. Oh, and H. B. Lee, “The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases,” Nature Reviews Nephrology, vol. 5, no. 4, pp. 203–211, 2009. View at: Publisher Site | Google Scholar
  33. J. H. Chang, S. Y. Paik, L. Mao et al., “Diabetic kidney disease in FVB/NJ Akita mice: temporal pattern of kidney injury and urinary nephrin excretion,” PLoS ONE, vol. 7, no. 4, Article ID e33942. View at: Publisher Site | Google Scholar
  34. Y. Wang, S. Zhao, S. Loyd, and L. J. Groome, “Increased urinary excretion of nephrin, podocalyxin, and betaig-h3 in women with preeclampsia,” American Journal of Physiology, vol. 302, no. 9, pp. F1084–F1089, 2012. View at: Publisher Site | Google Scholar
  35. V. S. Vaidya, V. Ramirez, T. Ichimura, N. A. Bobadilla, and J. V. Bonventre, “Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury,” American Journal of Physiology, vol. 290, no. 2, pp. F517–F529, 2006. View at: Publisher Site | Google Scholar
  36. V. S. Sabbisetti, K. Ito, C. Wang et al., “Novel assays for detection of urinary Kim-1 in mouse models of kidney injury,” Toxicological Sciences, vol. 131, no. 1, pp. 13–25, 2013. View at: Publisher Site | Google Scholar
  37. P. Ronco, “Proteinuria: is it all in the foot?” Journal of Clinical Investigation, vol. 117, no. 8, pp. 2079–2082, 2007. View at: Publisher Site | Google Scholar
  38. V. D. D'Agati, “Podocyte injury in focal segmental glomerulosclerosis: lessons from animal models (a play in five acts),” Kidney International, vol. 73, no. 4, pp. 399–406, 2008. View at: Publisher Site | Google Scholar
  39. F. T. H. Lee, Z. Cao, D. M. Long et al., “Interactions between angiotensin II and NF-κB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2139–2151, 2004. View at: Publisher Site | Google Scholar
  40. M. Nagata, K. Scharer, and W. Kriz, “Glomerular damage after uninephrectomy in young rats. I. Hypertrophy and distortion of capillary architecture,” Kidney International, vol. 42, no. 1, pp. 136–147, 1992. View at: Google Scholar
  41. J. M. Turner, C. Bauer, M. K. Abramowitz, M. L. Melamed, and T. H. Hostetter, “Treatment of chronic kidney disease,” Kidney International, vol. 81, pp. 351–362, 2012. View at: Publisher Site | Google Scholar
  42. J. A. Chavez and S. A. Summers, “Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms,” Biochimica et Biophysica Acta, vol. 1801, no. 3, pp. 252–265, 2010. View at: Publisher Site | Google Scholar
  43. M. N. Jensen and M. Ritskes-Hoitinga, “How isoflavone levels in common rodent diets can interfere with the value of animal models and with experimental results,” Laboratory Animals, vol. 41, no. 1, pp. 1–18, 2007. View at: Publisher Site | Google Scholar
  44. K. D. R. Setchell, “Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones,” American Journal of Clinical Nutrition, vol. 68, supplement 6, pp. 1333S–1346S, 1998. View at: Google Scholar
  45. K. Sharma, S. RamachandraRao, G. Qiu et al., “Adiponectin regulates albuminuria and podocyte function in mice,” Journal of Clinical Investigation, vol. 118, no. 5, pp. 1645–1656, 2008. View at: Publisher Site | Google Scholar
  46. A. A. Eddy and A. B. Fogo, “Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action,” Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 2999–3012, 2006. View at: Publisher Site | Google Scholar
  47. R. B. Goldberg, “Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3171–3182, 2009. View at: Publisher Site | Google Scholar
  48. D. P. K. Ng, B. C. Tai, E. Tan et al., “Nephrinuria associates with multiple renal traits in type 2 diabetes,” Nephrology Dialysis Transplantation, vol. 26, no. 8, pp. 2508–2514, 2011. View at: Publisher Site | Google Scholar
  49. M. A. Saleh, E. I. Boesen, J. S. Pollock, V. J. Savin, and D. M. Pollock, “Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes,” Diabetologia, vol. 54, no. 4, pp. 979–988, 2011. View at: Publisher Site | Google Scholar
  50. Group CKDW, “VA/DoD clinical practice guideline for the management of chronic kidney disease in primary care. Version 2.0,” in Veterans Health Administration (VHA) DoVAV, Department of Defense (DoD), Ed., Veterans Health Administration and Department of Defense, Washingon DC, USA, 2008. View at: Google Scholar
  51. National Kidney Foundation, “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, no. 2, supplement 1, pp. S1–S266, 2002. View at: Google Scholar

Copyright © 2013 Stephen P. O'Brien et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

2505 Views | 1113 Downloads | 10 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.